Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.07 USD
−135.96 M USD
0.00 USD
74.05 M
About Atea Pharmaceuticals, Inc.
Sector
CEO
Jean-Pierre Sommadossi
Headquarters
Boston
Website
Founded
2012
FIGI
BBG00TZNCJ75
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AVIR is 3.37 USD — it has increased by 2.85% in the past 24 hours. Watch Atea Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Atea Pharmaceuticals, Inc. stocks are traded under the ticker AVIR.
AVIR stock has fallen by −3.85% compared to the previous week, the month change is a −8.71% fall, over the last year Atea Pharmaceuticals, Inc. has showed a 17.01% increase.
We've gathered analysts' opinions on Atea Pharmaceuticals, Inc. future price: according to them, AVIR price has a max estimate of 6.20 USD and a min estimate of 6.20 USD. Watch AVIR chart and read a more detailed Atea Pharmaceuticals, Inc. stock forecast: see what analysts think of Atea Pharmaceuticals, Inc. and suggest that you do with its stocks.
AVIR reached its all-time high on Feb 11, 2021 with the price of 94.17 USD, and its all-time low was 2.77 USD and was reached on Nov 22, 2023. View more price dynamics on AVIR chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AVIR stock is 4.79% volatile and has beta coefficient of 1.54. Track Atea Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Atea Pharmaceuticals, Inc. there?
Today Atea Pharmaceuticals, Inc. has the market capitalization of 274.50 M, it has increased by 0.93% over the last week.
Yes, you can track Atea Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Atea Pharmaceuticals, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
AVIR earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.43 USD resulting in a 13.29% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Atea Pharmaceuticals, Inc. earnings.
Atea Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
AVIR net income for the last quarter is −31.15 M USD, while the quarter before that showed −40.52 M USD of net income which accounts for 23.13% change. Track more Atea Pharmaceuticals, Inc. financial stats to get the full picture.
No, AVIR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 75.00 employees. See our rating of the largest employees — is Atea Pharmaceuticals, Inc. on this list?
Like other stocks, AVIR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Atea Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Atea Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Atea Pharmaceuticals, Inc. stock shows the sell signal. See more of Atea Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.